Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Visen Reports Successful Phase III Trial of Hypoparathyroidism Therapy

publication date: Aug 12, 2024

Shanghai Visen Pharmaceuticals reported positive data from a China Phase III trial of its hypoparathyroidism therapy. In the 26-week trial, 77.6% of patients treated with palopegteriparatide, a parathyroid, met the primary endpoint compared to none in the placebo. Palopegteriparatide (TransCon PTH) is an investigational prodrug of PTH (1-34), administered once daily. Its sustained release of active PTH is designed to provide PTH levels in the physiological range for 24 hours/day. Visen, a biopharma focused on endocrine diseases, acquired China rights to the drug from Ascendis Pharma of Copenhagen. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here